Nerve agents

Neurologist

Volumn 13, Issue 1, 2007, Pages 20-32

  Newmark, Jonathan ^a,b,c  

^a Joint Program Executive Office for Chemical and Biological Defense   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c Skyline #2   (United States)

Author keywords

Chemical warfare agent; Cholinergic crisis; Nerve agent; Sarin; Soman; Tabun; VX

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 2 PRALIDOXIME; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ATROPINE; BENZODIAZEPINE; CARBAMAZEPINE; CHEMICAL WARFARE AGENT; CHLORINE; CHOLINESTERASE; DANTROLENE; DEXANABINOL; DIAZEPAM; LAMOTRIGINE; MIDAZOLAM; NERVE GAS; OBIDOXIME; ORGANOPHOSPHATE; OXIME DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PHOSGENE; PYRIDOSTIGMINE; SARIN; SCAVENGER; SOMAN; TABUN; UNCLASSIFIED DRUG; VALPROIC ACID;

APNEA; BRONCHOSPASM; CHEMICAL WARFARE; CLINICAL FEATURE; DIAPHRAGM PARALYSIS; DRUG MEGADOSE; ELECTROMYOGRAM; ENZYME INHIBITION; EPILEPTIC STATE; FASCICULATION; HEAD INJURY; HEART DISEASE; HUMAN; HYPERTENSION; LABORATORY TEST; LETHAL DOSE; LOADING DRUG DOSE; MONOTHERAPY; MUSCLE TWITCH; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SELF INJECTION; SYNAPSE; WAR;

ANIMALS; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEUROTOXICITY SYNDROMES; PYRIDOSTIGMINE BROMIDE;

EID: 33846247849     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000252923.04894.53     Document Type: Review

References (58)

1. Gunderson CH, Lehmann CR, Sidell FR, et al. Nerve agents: a review. Neurology. 1992;42:946-950.
2. Yokoyama K, Yamada A, Nobuhide M. Clinical profiles of patients with sarin poisoning after the Tokyo subway attack. Am J Med. 1996;100:586.
3. Foroutan SA. Medical notes on chemical warfare, part I-XI [in Farsi]. Kowsar Med J. 1996-1999;Vols. 1-4.
4. Sidell FR. Nerve agents. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine. Washington, DC: Office of the Surgeon General and Department of the Army and the Borden Institute; 1997:129-180.
5. Pelletiere SC, Johnson DV. Lessons Learned: The Iran-Iraq War. Carlisle Barracks, PA: Strategic Studies Institute, US Army War College; 1991.
6. Cordesman AH, Wagner AP. The Lessons of Modern War, Volume II: The Iran-Iraq War. Boulder, CO: Westview Press; 1990.
7. Dingeman A, Jupa R. Chemical warfare in the Iran-Iraq conflict. Strategy Tactics Magazine. 1987;113:51-52.
8. Barnaby F. Iran-Iraq war: the use of chemical weapons against the Kurds. Ambio. 1988;17:407-408.
9. Okumura T, Takasu N, Ishimatsu S, et al. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med. 1996;28:129-135.
10. Murakami H. Underground [English translation by Gabriel P]. New York: Vintage Books; 2001.
11. Departments of the Army, Navy, and Air Force, and Commandant, Marine Corps. Field Manual: Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Washington, DC: Departments of the Army, Navy, and Air Force, and Commandant, Marine Corps; 1995. This publication bears the following serial numbers: Army FM 8-285; Navy NAVMED P-5041; Air Force AFJMAN 44-149; and Marine Corps FMFM 11-11.
12. Chemical Casualty Care Division, US Army Medical Research Institute of Chemical Defense. Medical Management of Chemical Casualties Handbook. 3rd ed. Aberdeen Proving Ground, MD: Chemical Casualty Care Division, US Army Medical Research Institute of Chemical Defense; 2000.
13. Rotenberg JS, Newmark J. Nerve agent attacks on children: diagnosis and management. Pediatrics. 2003;112:648-658.
14. Kawana N, Ishimatsu S, Kanda K. Psycho-physiological effects of the terrorist sarin attack on the Tokyo subway system. Mil Med. 2001;166(suppl 2):23-26.
15. Murata K, Araki S, Yokoyama K, et al. Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous system six months after the Tokyo subway attack. J Neurol. 1997;244:601-606.
16. McDonough JH. Performance effects of nerve agents and their pharmacological countermeasures. Mil Psychol. 2002;14:93-119.
17. Hatta K, et al. Amnesia from sarin poisoning. Lancet. 1996;347:1343.
18. Evans ES, Olds KL, Weyandt TB. Pesticides. In: Deeter DP, Gaydos JC, eds. Occupational Health: The Soldier and the Industrial Base. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine. Washington, DC: US Department of the Army Office of the Surgeon General, and Borden Institute; 1993:532-536.
19. Van Hooidonk C, Ceulen BI, Bock J, et al. Chemical warfare agents and the skin: penetration and decontamination. Proceedings of the International Symposium on Protection against Chemical Warfare Agents, Stockholm, Sweden, June 6-9, 1983:153-160.
20. Rodgers JC. Chemical incident planning: a review of the literature. Accid Emerg Nurs. 1998;6:155-159.
21. Newmark J. The birth of nerve agent warfare: lessons from Syed Abbas Foroutan. Neurology. 2004;62:1590-1596.
22. Foltin G, Tunik M, Curran J, et al. Pediatric nerve agent poisoning: medical and operational considerations for emergency medical services in a large American city. Pedatr Emerg Care. 2006;22:239-244.
23. Sidell FR. Clinical considerations in nerve agent intoxication. In: Somani SM, ed. Chemical Warfare Agents. New York, NY: Academic Press; 1992:155-194.
24. Dunn MA, Hackley BE, Sidell FR. Pretreatment for nerve agent exposure. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine. Washington, DC: Office of the Surgeon General, Department of the Army and the Borden Institute; 1997:181-196.
25. Kuca K, Cabal J, Kassa J, et al. A comparison of the potency of the oxime HLo-7 and currently used oximes (HI-6, pralidoxime, obidoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. Acta Med (Hradec Kralove). 2005;48:81-86.
26. Kuca K, Juna D, Musilek K. Structural requirements of cholinesterase reactivators. Mini Rev Med Chem. 2006;6:269-277.
27. Worek F, Szinicz L, Thiermann H. Estimation of oxime efficacy in nerve agent poisoning: a kinetic approach. Chem Biol Interact. 2005;157-158:349-352.
28. Shih T, McDonough JH, Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci. 1999;6:86-96.
29. McDonough JH, Benjamin A, McMonagle JD, et al. Effects of fosphenytoin on nerve agent-induced status epilepticus. Drug Chem Toxicol. 2004;27:27-39.
30. Shih TM, McDonough JH. Neurochemical mechanisms in soman-induced seizures. J Appl Toxicol. 1997;17:255-264.
31. McDonough J, McMonagle J, Copeland T, et al. Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol. 1999;73:473-478.
32. McDonough JH Jr, Zoeffel LD, McMonagle J, et al. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res. 2000;38:1-14.
33. Capacio BR, Byers CE, Merk KA, et al. Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. Drug Chem Toxicol. 2004;27:95-110.
34. Gilat E, Kadar T, Levy A, et al. Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats. Toxicol Appl Pharmacol. 2005;209:74-85.
35. Shih TM, Duniho SM, McDonough JH. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol. 2003;188:69-80.
36. Koplovitz I, Schulz S, Shutz M, et al. Combination anticonvulsant treatment of soman-induced seizures. J Appl Toxicol. 2001;21(suppl 1):S53-S55.
37. Feldman RG. Organophosphorus compounds. In: Occupational and Environmental Neurotoxicology. Philadelphia: Lippincott-Raven; 1999:421-442.
38. Senanayake N, Johnson MK. Acute polyneuropathy after poisoning by a new organophosphate insecticide. N Engl J Med. 1982;306:155-157.
39. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. N Engl J Med. 1987;316:761-763.
40. Rosenberg NL. Occupational and Environmental Neurology. Boston: Butterworth-Heinemann; 1995:204-208.
41. Wadia RS, Chitra S, Amin RB, et al. Electrophysiological studies in acute organophosphorus poisoning. J Neurol Neurosurg Psychiatry. 1987;50:1442-1448.
42. Himuro K, et al. Distal sensory neuropathy after sarin intoxication. Neurology. 1995;51:1195-1197.
43. Willems JL, Nicaise M, De Bisschop HC. Delayed neuropathy by the organophosphorus nerve agents soman and tabun. Arch Toxicol. 1984;55:76-77.
44. Goldstein BD, Fincher DR, Searle JR. Electrophysiological changes in the primary sensory neuron following subchronic soman and sarin: alterations in sensory receptor function. Toxicol Appl Pharmacol. 1987;91:55-64.
45. Baker DJ, Sedgwick EM. Single fibre electromyographic changes in man after organophosphate exposure. Hum Exp Toxicol. 1996;15:369-375.
46. Duffy FH, Burchfiel JL, Bartels PH, et al. Long-term effects of an organophosphate upon the human electroencephalogram. Toxicol Appl Pharmacol. 1979;47:161-176.
47. Craig AB, Freeman G. Clinical Observations on Workers Accidentally Exposed to "G" Agents. Edgewood Arsenal, MD: Medical Research Laboratory; 1953. Medical Laboratory Research Report 154.
48. Brody BB, Gammill JF. Seventy-five Cases of Accidental Nerve Gas Poisoning at Dugway Proving Ground. Dugway Proving Ground, UT: Medical Investigational Branch; 1954. Medical Investigational Branch Special Report 5.
49. Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol. 1974;7:1-17.
50. Grob D. The manifestations and treatment of poisoning due to nerve agents and other organic phosphate anticholinesterase compounds. Arch Intern Med. 1956;98:221-239.
51. Ohbu S, Yamashina A, Takasu N, et al. Sarin poisoning on Tokyo subway. South Med J. 1997;90:587-592.
52. Brown MA, Brix KA. Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. J Appl Toxicol. 1998;18:393-408.
53. Filbert MG, Forster JS, Smith CD, et al. Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures. Ann N Y Acad Sci. 1999;890:505-514.
54. Newmark J, Ballough GPH, Filbert MG. Dantrolene plus diazepam: a viable strategy for neuroprotection following soman-induced status epilepticus. Neurology. 2003;60(suppl 1):A385.
55. Mion G, Tourtier JP, Petitjeans F, et al. Neuroprotective and antiepileptic activities of ketamine in nerve agent poisoning. Anesthesiology. 2003;98:1517.
56. Cerasoli DM, Lenz DE. Nerve agent bioscavengers: protection with reduced behavioral effects. Mil Psychol. 2002;14:121-143.
57. Lenz DE, Maxwell DM, Koplovitz I, et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact. 2005;157-158:205-210.
58. Cerasoli DM, Griffiths EM, Doctor BP, et al. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005;157-158:363-365.